Global health coalition urges G20 pledge on pandemics and neglected diseases

The Coalition of Global Health Organisations has called on the G20 to provide leadership in combating pandemics, drug resistance, and major poverty-related and neglected diseases.

This "Call to Action", launched in Berlin on Friday April 28, strongly urges the G20 to commit investment in research, innovation and development of innovative health technologies to counter threats posed by Antimicrobial Resistance (AMR), Poverty-Related and Neglected Diseases (PRNDs) and pandemics.

We call on the G20 to agree to take the following actions:

Provide political support to address the inter-related issues of AMR, pandemic preparedness/ response and PRNDs

• Include a commitment to research and development (R&D) of products and interventions for global health in the outcome document of the Meeting of the G20 Ministers of Health, in the G20 Communiqué and in all relevant G20 agendas, with a focus on addressing the threat of a broad spectrum of emerging antimicrobial resistance from a variety of bacteria, parasites, viruses and fungi, as well as emerging infectious diseases

Increase financial support and its co-ordination across the G20 and partner countries to ensure sustainable, long-term funding for global health innovation, with a focus on AMR, pandemic preparedness/ response and PRNDs.

• Coordinate funding between G20 countries to ensure inefficiencies and duplication of efforts are avoided, and that the significant costs of product development are shared among nations.

Encourage business, philanthropic organizations and other financing institutions from the G20 to increase investment in global health innovation, in the interrelated areas of AMR, pandemic preparedness / response and PRNDs.

• Promote financial support to the work of multinational partnership mechanisms such as Product Development Partnerships (PDPs) and other public-private collaborations to expand global health innovation.

Mobilize G20 public health and scientific expertise to address antimicrobial resistance (AMR) in both neglected and major poverty diseases by:

• Supporting global efforts to develop new tools, interventions and approaches to address AMR.
• Assisting low and middle-income G20 partner countries in building up their research and product development capacity for the fight against AMR.
• Promoting open data sharing in R&D to help technology transfers and strengthening of research capacity in G20 and partner countries to address AMR.

The Coalition includes the following organisations:

• TB Alliance
  
• Medicines for Malaria Venture
  
• PATH
  
• Sabin Vaccine Institute
  
• CARB-X
  
• CEPI
  
• Global Health Technologies Coalition
  
• GHIT Fund
• UNITAID
• Sovereign Strategy